Neurizon Therapeutics Limited has released a press release.
MND Trial Completes Enrolment of Cohort 2
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Stable Patient in MND trial reaches 6-months on MPL
- Canine Cancer Trial Update
- Interim analysis recommended in MND trial
- European Patent relating to MPL Combinations in Cancer
- First Patient of Cohort 2 Dosed in MND Trial
Later from Neurizon Therapeutics
- PharmAust launches international CEO search
- Arrival of additional MPL tablets
- MND Trial Successfully Completes Second Patient Cohort
- PharmAust Raises $2.5m via Placement
- MPL has anti-cancer effects across multiple cancer types
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics